立方制药(003020) - 2022 Q4 - 年度财报

Share Capital and Equity Structure - The company's total share capital increased from 92,640,000 shares to 120,432,000 shares after a capital reserve transfer of 3 shares for every 10 shares held, resulting in an additional 27,792,000 shares[3][7] - The restricted shares increased from 54,101,850 shares to 71,595,385 shares, with a total increase of 17,493,535 shares due to capital reserve transfers and other factors[3][6] - The company issued 2.035 million restricted shares as part of its 2022 equity incentive plan, increasing the total share capital from 120,432,000 shares to 122,467,000 shares[7] - Tang Zhongxian, a former supervisor, holds 394,680 shares that are locked until February 28, 2023, due to his resignation[4] - Dai Tianhe, appointed as vice president, holds 274,740 shares, with 75% (206,055 shares) locked during his tenure[4] - The largest shareholder, Hefei Lifang Investment Group Co., Ltd., holds 24,024,000 restricted shares, which will be unlocked on December 15, 2023[5] - The equity incentive plan includes 2,035,000 restricted shares, with 814,000 shares to be unlocked on October 19, 2023, and the remaining in subsequent years[5] - The company's registered capital as of December 31, 2022 was RMB 120,432,000.00, with a total share capital of 122,467,000 shares[41] - The company's share capital increased by RMB 29,827,000.00 in 2022, reaching RMB 92,640,000.00[36] Financial Performance - Total revenue for 2022 reached 2,579,340,227.28 yuan, a significant increase from 2,273,254,476.86 yuan in 2021[21] - Operating costs for 2022 amounted to 2,376,803,278.74 yuan, compared to 2,096,710,520.90 yuan in 2021[21] - R&D expenses increased to 73,803,566.10 yuan in 2022 from 65,857,993.22 yuan in 2021[21] - Operating profit for 2022 increased to 240,054,921.89 RMB, up from 192,454,402.58 RMB in 2021[22] - Net profit for 2022 rose to 209,607,566.84 RMB, compared to 172,227,170.61 RMB in 2021[22] - Basic and diluted earnings per share (EPS) for 2022 were 1.74, up from 1.43 in 2021[23] - Total revenue for 2022 reached 921,990,714.66 RMB, an increase from 833,474,534.39 RMB in 2021[27] - R&D expenses for 2022 were 71,006,207.68 RMB, up from 62,863,374.18 RMB in 2021[27] - Total liabilities for 2022 increased to 641,534,824.26 RMB, compared to 370,534,154.24 RMB in 2021[24] - Total equity for 2022 stood at 1,480,221,061.41 RMB, up from 1,303,910,770.75 RMB in 2021[25] - Cash flow from operating activities for 2022 was 126,712,592.89 RMB, down from 150,318,002.40 RMB in 2021[29] - Sales revenue from goods and services in 2022 was 2,484,446,384.96 RMB, up from 2,034,582,976.76 RMB in 2021[28] - Total assets for 2022 increased to 2,121,755,885.67 RMB, compared to 1,674,444,924.99 RMB in 2021[25] - Comprehensive income for 2022 was RMB 209,607,566.84[31] - Owner's equity increased by RMB 176,310,290.66 in 2022[31] - The company's total owner's equity at the end of 2022 was RMB 1,150,508,723.99, an increase of RMB 110,588,041.31 compared to the previous year[36][39] - Comprehensive income for 2022 was RMB 185,410,681.20, a significant increase from RMB 152,897,572.20 in 2021[36][39] - Revenue in 2022 reached 2.579 billion yuan, a year-on-year increase of 13.46%[153] - Net profit attributable to shareholders in 2022 was 209.61 million yuan, a year-on-year increase of 21.70%[153] - Net cash flow from operating activities in 2022 was 200.64 million yuan, a year-on-year increase of 26.42%[153] - Total assets at the end of 2022 were 2.122 billion yuan, a year-on-year increase of 26.71%[153] - The company's total revenue for 2022 was 2.579 billion yuan, a year-on-year increase of 13.46%[172] - Revenue from the pharmaceutical retail sector increased by 35.68% to 129.69 million yuan[172] - The company's pharmaceutical industrial sector generated revenue of 965.52 million yuan, accounting for 37.43% of total revenue[172] - The company's pharmaceutical wholesale and distribution sector revenue increased by 15.74% to 1.475 billion yuan[172] - The company's production volume in the pharmaceutical industry increased by 77.48% to 117.68 million units[169] - The company's inventory in the pharmaceutical industry increased by 496.47% to 41.22 million units[169] - The company's sales volume in the pharmaceutical industry increased by 30.56% to 84.37 million units[169] - The company's R&D expenses increased by 12.06% to 73.80 million yuan[174] - The company's management expenses increased by 31.83% to 59.14 million yuan, mainly due to equity incentive costs[174] - The company's financial expenses decreased by 121.63% to -3.55 million yuan, mainly due to increased interest income and exchange rate changes[174] - R&D investment in 2022 was RMB 76,895,433.08, a 6.01% increase compared to 2021[176] - R&D investment accounted for 2.98% of total revenue in 2022, a slight decrease of 0.21% from 2021[176] - Capitalized R&D investment decreased by 11.58% to RMB 650,400 in 2022[176] - Net cash flow from operating activities increased by 26.42% to RMB 200,638,124.66 in 2022[176] - Net cash flow from investing activities was negative RMB 201,804,837.88, a 5.17% increase in outflow compared to 2021[176] - Cash and cash equivalents decreased by 46.97% to RMB 642,579,832.93 at the end of 2022[179] - Inventory increased by 5.77% to RMB 361,764,867.19, mainly due to increased raw material and centralized procurement product stock[179] - Construction in progress increased by 8.29% to RMB 340,892,548.01, driven by fundraising project construction[179] Asset and Liability Structure - Fixed assets grew to 182,376,394.47 yuan in 2022 from 141,887,846.59 yuan in 2021[20] - Construction in progress surged to 340,892,548.01 yuan in 2022 from 130,349,242.59 yuan in 2021[20] - Total assets increased to 2,121,755,885.67 yuan in 2022 from 1,674,444,924.99 yuan in 2021[20] - Accounts payable rose to 246,935,013.64 yuan in 2022 from 149,252,042.76 yuan in 2021[20] - Contract liabilities increased to 42,615,546.58 yuan in 2022 from 14,690,780.16 yuan in 2021[20] - Long-term equity investments decreased to 14,397,960.96 yuan in 2022 from 20,707,582.59 yuan in 2021[20] - Deferred tax assets grew to 8,938,426.84 yuan in 2022 from 5,859,398.31 yuan in 2021[20] - The company's asset and liability structure remained unchanged after the capital reserve transfer[7] - The top 10 shareholders did not engage in any agreed repurchase transactions during the reporting period[9] - Total owner's equity at the beginning of 2022 was RMB 1,303,910,770.75[31] - Capital reserve decreased by RMB 27,792,000.00 due to capital transfer[33] - Profit distribution to owners (or shareholders) was RMB -64,848,000.00[33] - General risk provision extraction was RMB 0.00[33] - Surplus reserve extraction was RMB 14,913,500.00[33] - Total owner's equity at the end of 2022 was RMB 1,480,221,061.41 (calculated from initial balance and increase)[31] - The company's capital reserve increased by RMB 7,143,950.46 in 2022, reaching RMB 526,163,987.29[36] - Retained earnings grew by RMB 105,649,181.20 in 2022, reaching RMB 485,384,736.70[36] - The company distributed RMB 64,848,000.00 to shareholders in 2022, compared to RMB 46,320,000.00 in 2021[36][39] - The company's surplus reserve increased by RMB 14,913,500.00 in 2022, reaching RMB 46,320,000.00[36] - The company's total assets increased by RMB 130,488,481.66 in 2022, primarily due to increased owner contributions and comprehensive income[36] Dividend Distribution - The company distributed a cash dividend of RMB 7.00 per 10 shares, totaling RMB 64,848,000[4] - The company distributed RMB 64,848,000.00 to shareholders in 2022, compared to RMB 46,320,000.00 in 2021[36][39] Business Operations and Strategy - The company has 5 consolidated subsidiaries, including Cube Pharmaceutical Co., Ltd. and Hefei Dayu Pharmaceutical Co., Ltd[42] - The company uses a 12-month operating cycle as the standard for dividing the liquidity of assets and liabilities[45] - For non-controlling business combinations achieved through multiple transactions, the company determines whether these transactions constitute a "package deal" based on specific criteria[46] - The company's financial statements comply with enterprise accounting standards and accurately reflect its financial status, operating results, and cash flows[47] - In non-controlling business combinations, the company recognizes goodwill if the merger cost exceeds the fair value of the identifiable net assets acquired[48] - If the fair value of assets or liabilities cannot be reasonably determined at the acquisition date, the company uses a provisional value and adjusts it within 12 months if necessary[49] - Transaction costs related to business combinations, such as audit and legal fees, are recognized as expenses in the current period[50] - Subsidiaries acquired through business combinations are included in the consolidated financial statements from the date of control[51] - The company adjusts capital reserves when purchasing minority equity or partially disposing of subsidiary equity without losing control[52] - The company classifies joint arrangements as either joint operations or joint ventures and accounts for them accordingly[53] - The company uses the spot exchange rate on the transaction date for foreign currency transactions, with exceptions for specific scenarios such as capitalizable assets and effective hedges[54] - Interest income is calculated based on the financial asset's carrying amount multiplied by the effective interest rate, with adjustments for credit-impaired assets[55] - Financial assets measured at fair value through other comprehensive income (FVOCI) are managed with a business model aimed at both collecting contractual cash flows and selling the asset[55] - Non-trading equity investments can be irrevocably designated as FVOCI at initial recognition, with gains or losses recognized in other comprehensive income[58] - Financial assets measured at fair value through profit or loss (FVTPL) are recognized at fair value, with gains or losses recorded in profit or loss[58] - The company recognizes the difference between the carrying amount and the consideration received for transferred financial assets in profit or loss[59] - Financial liabilities are derecognized when the obligation is discharged, and any difference between the carrying amount and consideration paid is recognized in profit or loss[60] - The company uses valuation techniques supported by sufficient data to determine the fair value of financial instruments[60] - Expected credit losses for receivables are measured based on the present value of the difference between contractual and expected cash flows[62] - Receivables financing is grouped based on credit risk characteristics, with expected credit losses estimated using historical data and forward-looking information[63] - Inventory is measured at the lower of cost or net realizable value, with net realizable value determined based on estimated selling price minus estimated costs to complete, selling expenses, and related taxes[66][71] - The company uses the perpetual inventory system for inventory management[67] - Contract assets are recognized when the company has a right to consideration for goods transferred to customers, contingent on factors other than time passage[68] - Contract assets and liabilities under the same contract are presented net on the balance sheet[68] - Contract costs include both contract acquisition costs and contract fulfillment costs, recognized as assets if they meet specific criteria[69] - Assets related to contract costs are amortized on the same basis as revenue recognition for the related goods or services[69] - Non-current assets or disposal groups classified as held for sale are measured at the lower of carrying amount or fair value less costs to sell[70][73] - The company classifies assets as held for sale when they meet specific criteria, including being available for immediate sale and having a highly probable sale within one year[72] - Inventory impairment is assessed at the individual item level, but for large quantities of low-value items, impairment is assessed at the category level[71] - Contract asset impairment is measured based on the present value of the difference between contractual cash flows and expected cash flows[68] - The fair value of disposal groups held for sale after the balance sheet date increases, and the previously written-down amount should be recovered and recognized within the scope of non-current assets measured under the No. 42 standard. The recovery amount is allocated proportionally based on the book value of each non-current asset in the disposal group, excluding goodwill, and is recorded in current profits and losses[75] - Long-term equity investments include equity investments in subsidiaries, joint ventures, and associates where the company has control, joint control, or significant influence[76] - For long-term equity investments accounted for using the equity method, if the initial investment cost is greater than the fair value of the identifiable net assets of the investee, the initial investment cost is not adjusted. If it is less, the difference is recognized in current profits and losses and the investment cost is adjusted[79] - When the company disposes of long-term equity investments, the difference between the book value and the actual proceeds is recognized in current profits and losses[81] - If the company loses control of a subsidiary due to partial disposal of equity investments, the remaining equity is accounted for using the equity method, and adjustments are made as if the equity method had been applied from the date of acquisition[82] - The company capitalizes borrowing costs directly attributable to the acquisition or production of qualifying assets, while other borrowing costs are recognized as expenses in the period they are incurred[85] - The company capitalizes borrowing costs when specific conditions are met, including asset expenditure, borrowing costs, and necessary construction or production activities[86] - Borrowing costs are suspended if the construction or production of a capitalizable asset is interrupted abnormally for more than 3 months[86] - The company uses the straight-line method to depreciate right-of-use assets, with depreciation periods based on lease terms or asset remaining useful life[87] - Intangible assets are initially measured at cost, including purchase price, taxes, and other directly attributable expenses[88] - The estimated useful lives of intangible assets are determined based on factors such as product life cycles, technological trends, and market demand[89] - The company reviews the useful lives and amortization methods of finite-lived intangible assets annually, adjusting estimates if necessary[90] - Long-term assets are assessed for impairment if there are indications such as significant market price declines or adverse changes in economic or legal environments[91] - Long-term prepaid expenses are amortized over the benefit period or specified duration, with unamortized balances written off if future benefits are no longer expected[92] - Short-term employee benefits, including wages, bonuses, and social insurance contributions, are recognized as liabilities and expensed or capitalized during the service period[93] - Post-employment benefits are classified as defined contribution plans, with contributions recognized as liabilities and expensed or capitalized during the service period[95] - The company recognizes revenue when control of the goods is transferred to the customer, considering factors such as present payment obligation, legal ownership transfer, and physical possession[104] - Revenue from pharmaceutical wholesale and distribution is recognized upon customer receipt of the goods, provided that the payment is expected to be collected and the related costs can be reliably measured[107] - For pharmaceutical retail, revenue is recognized when the control of the goods is transferred to the customer, with sales typically settled via cash, bank cards, medical insurance cards, or Alipay[107] - The company allocates transaction prices to individual performance obligations based on the relative standalone selling prices of the goods promised in the contract[105] - Variable consideration in contracts is estimated using either the expected value or the most likely amount, ensuring that the total transaction price does not exceed the amount that is highly probable of not being subject to significant reversal[105] - The company accounts for significant financing components in contracts by determining the transaction price as if the customer had paid cash at the time control of the goods was transferred, with any difference amortized over the contract period using the effective interest method[105] - Government grants are classified as either asset-related or income-related, depending on their nature and purpose[107] - The company uses the lease liability method to account for leases, recognizing lease liabilities at the present value of lease payments not yet paid, and includes fixed payments, variable payments based on indices or rates, and expected payments for